2025 Q3 -tulosraportti
Vain PDF
115 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 940 | - | - | ||
| 14 184 | - | - | ||
| 6 506 | - | - | ||
| 255 | - | - | ||
| 500 | - | - |
Ylin
0,617VWAP
Alin
0,583VaihtoMäärä
0,1 141 996
VWAP
Ylin
0,617Alin
0,583VaihtoMäärä
0,1 141 996
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenInteresting to see when "Richard Rônblom", who has shorted it from a price around 0.847 on Dec 22-25, dares to keep it down here??? Probably, among other things, the 125K+ that have been at price 0.620 and pushed the price down for a couple of days now!- ·2 päivää sittenALZ participation in investor events until summer.... Alzinova plans to participate in the following events during 2026: Carnegie Healthcare Micro Cap Event – Digital, March 9, 2026 A digital investor event focusing on companies in the healthcare sector, where Alzinova will present the company's strategy and the development of ALZ-101. AD/PD Conference – Copenhagen, Denmark, March 17–21, 2026 One of the world's leading scientific conferences on Alzheimer's and Parkinson's disease, where researchers, clinicians, and pharmaceutical companies gather to discuss the latest developments in neurodegenerative diseases. BIO-Europe Spring – Lisbon, Portugal, March 23–25, 2026 One of Europe's most important partnering conferences in life science, where the company will meet international pharmaceutical companies, investors, and potential partners. Redeye Theme: Alzheimer's – Stockholm, Sweden, April 9, 2026 A theme event organized by Redeye focusing on companies active in the Alzheimer's field and the latest developments in disease-modifying treatments. BIO International Convention – San Diego, USA, June 22–25, 2026 One of the world's largest life science partnering conferences, where global pharmaceutical companies, investors, and biotechnology companies meet to explore collaborations and future development opportunities. Alzheimer's Association International Conference (AAIC) – London, United Kingdom, July 12–15, 2026 The largest global conference on Alzheimer's research, where leading researchers and industry representatives present new scientific and clinical advances in the field. Note especially BIO-Europe Spring – Lisbon, Portugal, March 23–25, 2026. One of Europe's most important partnering conferences!!!
- ·25.2.Alzinova AB - Beyond plaques: the scientific rationale behind ALZ-101 Equity analyst Maria Karlsson Osipova interviews Alzinova's CSO and co-founder Anders Sandberg about ALZ-101 and the scientific basis for Alzinova's vaccine strategy against Alzheimer's disease. https://www.linkedin.com/company/dnbcarnegieaccess/posts/?feedView=all
- ·24.2.If you ask ChatGPT whether Novo or Eli Lilly could be interested in ALZ, you get this answer: Here are the results for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? Search instead for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? AI Overview Yes, it is theoretically possible that large pharmaceutical companies like Eli Lilly or Novo Nordisk could find Alzinova AB interesting, primarily due to their specialization in Alzheimer's treatment. Alzinova develops promising, disease-modifying treatments that specifically target the toxic amyloid-beta oligomers, which are believed to be the cause of Alzheimer's disease. www.inderes.se www.inderes.se Here is an analysis of why Alzinova AB may be of interest: Alzinova AB's pipeline (Why they are interesting): ALZ-101 (Vaccine): Alzinova's leading candidate is a therapeutic vaccine that has shown good results in Phase 1b trials. It has good tolerability, an acceptable safety profile, and a high immune response rate. AβCC-peptide technology: The company uses a patented technology that precisely targets the harmful oligomers (small protein clumps), which can offer an advantage over previous antibody treatments that target both healthy and diseased proteins. Upcoming Phase 2 studies: Alzinova has received approval to start Phase 2 studies, including in the USA, which is a critical milestone that increases attractiveness for larger partners. National Institutes of Health (.gov) National Institutes of Health (.gov) +4 Interest from Eli Lilly: Eli Lilly is already a leading player in Alzheimer's treatment with donanemab (Kisunla). Since Alzinova focuses on "oligomer-specific" treatments, which are considered rare, ALZ-101 (the vaccine) could be a strategic supplement to Lilly's current antibody pipeline. Alzinova Alzinova +1 Interest from Novo Nordisk: Novo Nordisk has a strong interest in neurodegenerative diseases, including Alzheimer's, and has previously investigated the potential of semaglutide (although their EVOKE trial did not show the expected effect in delaying disease progression). As Novo Nordisk is actively looking for new projects and acquisitions (focus on "other projects and acquisitions" per Feb 2026), a specialized player like Alzinova could be interesting to diversify their portfolio. Overall assessment: It is a widespread practice for large pharmaceutical companies to acquire smaller biotech companies (like the Swedish Alzinova) when their candidates have shown positive "proof-of-concept" in Phase 1 and are moving into Phase 2, as this reduces risk. Alzinova's niche technology against oligomers makes them an attractive partner or acquisition candidate for a player who wants to be a leader in next-generation Alzheimer's treatment.·24.2.And then they get help from one of the gurus in Alzheimer's. - Henrik Zetterberg... https://biostock.se/en/2026/02/henrik-zetterberg-om-ny-era-inom-alzheimersbehandling/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
115 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenInteresting to see when "Richard Rônblom", who has shorted it from a price around 0.847 on Dec 22-25, dares to keep it down here??? Probably, among other things, the 125K+ that have been at price 0.620 and pushed the price down for a couple of days now!
- ·2 päivää sittenALZ participation in investor events until summer.... Alzinova plans to participate in the following events during 2026: Carnegie Healthcare Micro Cap Event – Digital, March 9, 2026 A digital investor event focusing on companies in the healthcare sector, where Alzinova will present the company's strategy and the development of ALZ-101. AD/PD Conference – Copenhagen, Denmark, March 17–21, 2026 One of the world's leading scientific conferences on Alzheimer's and Parkinson's disease, where researchers, clinicians, and pharmaceutical companies gather to discuss the latest developments in neurodegenerative diseases. BIO-Europe Spring – Lisbon, Portugal, March 23–25, 2026 One of Europe's most important partnering conferences in life science, where the company will meet international pharmaceutical companies, investors, and potential partners. Redeye Theme: Alzheimer's – Stockholm, Sweden, April 9, 2026 A theme event organized by Redeye focusing on companies active in the Alzheimer's field and the latest developments in disease-modifying treatments. BIO International Convention – San Diego, USA, June 22–25, 2026 One of the world's largest life science partnering conferences, where global pharmaceutical companies, investors, and biotechnology companies meet to explore collaborations and future development opportunities. Alzheimer's Association International Conference (AAIC) – London, United Kingdom, July 12–15, 2026 The largest global conference on Alzheimer's research, where leading researchers and industry representatives present new scientific and clinical advances in the field. Note especially BIO-Europe Spring – Lisbon, Portugal, March 23–25, 2026. One of Europe's most important partnering conferences!!!
- ·25.2.Alzinova AB - Beyond plaques: the scientific rationale behind ALZ-101 Equity analyst Maria Karlsson Osipova interviews Alzinova's CSO and co-founder Anders Sandberg about ALZ-101 and the scientific basis for Alzinova's vaccine strategy against Alzheimer's disease. https://www.linkedin.com/company/dnbcarnegieaccess/posts/?feedView=all
- ·24.2.If you ask ChatGPT whether Novo or Eli Lilly could be interested in ALZ, you get this answer: Here are the results for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? Search instead for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? AI Overview Yes, it is theoretically possible that large pharmaceutical companies like Eli Lilly or Novo Nordisk could find Alzinova AB interesting, primarily due to their specialization in Alzheimer's treatment. Alzinova develops promising, disease-modifying treatments that specifically target the toxic amyloid-beta oligomers, which are believed to be the cause of Alzheimer's disease. www.inderes.se www.inderes.se Here is an analysis of why Alzinova AB may be of interest: Alzinova AB's pipeline (Why they are interesting): ALZ-101 (Vaccine): Alzinova's leading candidate is a therapeutic vaccine that has shown good results in Phase 1b trials. It has good tolerability, an acceptable safety profile, and a high immune response rate. AβCC-peptide technology: The company uses a patented technology that precisely targets the harmful oligomers (small protein clumps), which can offer an advantage over previous antibody treatments that target both healthy and diseased proteins. Upcoming Phase 2 studies: Alzinova has received approval to start Phase 2 studies, including in the USA, which is a critical milestone that increases attractiveness for larger partners. National Institutes of Health (.gov) National Institutes of Health (.gov) +4 Interest from Eli Lilly: Eli Lilly is already a leading player in Alzheimer's treatment with donanemab (Kisunla). Since Alzinova focuses on "oligomer-specific" treatments, which are considered rare, ALZ-101 (the vaccine) could be a strategic supplement to Lilly's current antibody pipeline. Alzinova Alzinova +1 Interest from Novo Nordisk: Novo Nordisk has a strong interest in neurodegenerative diseases, including Alzheimer's, and has previously investigated the potential of semaglutide (although their EVOKE trial did not show the expected effect in delaying disease progression). As Novo Nordisk is actively looking for new projects and acquisitions (focus on "other projects and acquisitions" per Feb 2026), a specialized player like Alzinova could be interesting to diversify their portfolio. Overall assessment: It is a widespread practice for large pharmaceutical companies to acquire smaller biotech companies (like the Swedish Alzinova) when their candidates have shown positive "proof-of-concept" in Phase 1 and are moving into Phase 2, as this reduces risk. Alzinova's niche technology against oligomers makes them an attractive partner or acquisition candidate for a player who wants to be a leader in next-generation Alzheimer's treatment.·24.2.And then they get help from one of the gurus in Alzheimer's. - Henrik Zetterberg... https://biostock.se/en/2026/02/henrik-zetterberg-om-ny-era-inom-alzheimersbehandling/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 940 | - | - | ||
| 14 184 | - | - | ||
| 6 506 | - | - | ||
| 255 | - | - | ||
| 500 | - | - |
Ylin
0,617VWAP
Alin
0,583VaihtoMäärä
0,1 141 996
VWAP
Ylin
0,617Alin
0,583VaihtoMäärä
0,1 141 996
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
115 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenInteresting to see when "Richard Rônblom", who has shorted it from a price around 0.847 on Dec 22-25, dares to keep it down here??? Probably, among other things, the 125K+ that have been at price 0.620 and pushed the price down for a couple of days now!
- ·2 päivää sittenALZ participation in investor events until summer.... Alzinova plans to participate in the following events during 2026: Carnegie Healthcare Micro Cap Event – Digital, March 9, 2026 A digital investor event focusing on companies in the healthcare sector, where Alzinova will present the company's strategy and the development of ALZ-101. AD/PD Conference – Copenhagen, Denmark, March 17–21, 2026 One of the world's leading scientific conferences on Alzheimer's and Parkinson's disease, where researchers, clinicians, and pharmaceutical companies gather to discuss the latest developments in neurodegenerative diseases. BIO-Europe Spring – Lisbon, Portugal, March 23–25, 2026 One of Europe's most important partnering conferences in life science, where the company will meet international pharmaceutical companies, investors, and potential partners. Redeye Theme: Alzheimer's – Stockholm, Sweden, April 9, 2026 A theme event organized by Redeye focusing on companies active in the Alzheimer's field and the latest developments in disease-modifying treatments. BIO International Convention – San Diego, USA, June 22–25, 2026 One of the world's largest life science partnering conferences, where global pharmaceutical companies, investors, and biotechnology companies meet to explore collaborations and future development opportunities. Alzheimer's Association International Conference (AAIC) – London, United Kingdom, July 12–15, 2026 The largest global conference on Alzheimer's research, where leading researchers and industry representatives present new scientific and clinical advances in the field. Note especially BIO-Europe Spring – Lisbon, Portugal, March 23–25, 2026. One of Europe's most important partnering conferences!!!
- ·25.2.Alzinova AB - Beyond plaques: the scientific rationale behind ALZ-101 Equity analyst Maria Karlsson Osipova interviews Alzinova's CSO and co-founder Anders Sandberg about ALZ-101 and the scientific basis for Alzinova's vaccine strategy against Alzheimer's disease. https://www.linkedin.com/company/dnbcarnegieaccess/posts/?feedView=all
- ·24.2.If you ask ChatGPT whether Novo or Eli Lilly could be interested in ALZ, you get this answer: Here are the results for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? Search instead for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? AI Overview Yes, it is theoretically possible that large pharmaceutical companies like Eli Lilly or Novo Nordisk could find Alzinova AB interesting, primarily due to their specialization in Alzheimer's treatment. Alzinova develops promising, disease-modifying treatments that specifically target the toxic amyloid-beta oligomers, which are believed to be the cause of Alzheimer's disease. www.inderes.se www.inderes.se Here is an analysis of why Alzinova AB may be of interest: Alzinova AB's pipeline (Why they are interesting): ALZ-101 (Vaccine): Alzinova's leading candidate is a therapeutic vaccine that has shown good results in Phase 1b trials. It has good tolerability, an acceptable safety profile, and a high immune response rate. AβCC-peptide technology: The company uses a patented technology that precisely targets the harmful oligomers (small protein clumps), which can offer an advantage over previous antibody treatments that target both healthy and diseased proteins. Upcoming Phase 2 studies: Alzinova has received approval to start Phase 2 studies, including in the USA, which is a critical milestone that increases attractiveness for larger partners. National Institutes of Health (.gov) National Institutes of Health (.gov) +4 Interest from Eli Lilly: Eli Lilly is already a leading player in Alzheimer's treatment with donanemab (Kisunla). Since Alzinova focuses on "oligomer-specific" treatments, which are considered rare, ALZ-101 (the vaccine) could be a strategic supplement to Lilly's current antibody pipeline. Alzinova Alzinova +1 Interest from Novo Nordisk: Novo Nordisk has a strong interest in neurodegenerative diseases, including Alzheimer's, and has previously investigated the potential of semaglutide (although their EVOKE trial did not show the expected effect in delaying disease progression). As Novo Nordisk is actively looking for new projects and acquisitions (focus on "other projects and acquisitions" per Feb 2026), a specialized player like Alzinova could be interesting to diversify their portfolio. Overall assessment: It is a widespread practice for large pharmaceutical companies to acquire smaller biotech companies (like the Swedish Alzinova) when their candidates have shown positive "proof-of-concept" in Phase 1 and are moving into Phase 2, as this reduces risk. Alzinova's niche technology against oligomers makes them an attractive partner or acquisition candidate for a player who wants to be a leader in next-generation Alzheimer's treatment.·24.2.And then they get help from one of the gurus in Alzheimer's. - Henrik Zetterberg... https://biostock.se/en/2026/02/henrik-zetterberg-om-ny-era-inom-alzheimersbehandling/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 940 | - | - | ||
| 14 184 | - | - | ||
| 6 506 | - | - | ||
| 255 | - | - | ||
| 500 | - | - |
Ylin
0,617VWAP
Alin
0,583VaihtoMäärä
0,1 141 996
VWAP
Ylin
0,617Alin
0,583VaihtoMäärä
0,1 141 996
Välittäjätilasto
Dataa ei löytynyt